Glenmark Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on Glenmark Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Glenmark Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Glenmark Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Glenmark Pharmaceuticals Catalyst Calendar
Proactively evaluate Glenmark Pharmaceuticals Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Glenmark Pharmaceuticals Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 15 Feb 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 31 Jan 2020 | Phase III Trial Initiation | Glenmark Pharmaceuticals Ltd | GLENMARK | (remogliflozin etabonate + vildagliptin) | Metabolic Disorders | Type 2 Diabetes | Clinical Trial Registry |
| 01 Dec 2019 | Phase I Trial Initiation | Glenmark Pharmaceuticals Ltd | GLENMARK | ISB-1342 | Oncology | Solid Tumor | Company Press Release |
| 01 Dec 2019 | Phase I Trial Initiation | Glenmark Pharmaceuticals Ltd | GLENMARK | ISB-1302 | Oncology | Breast Cancer; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer